Tasmanian devil vaccine and immunology workshop in Melbourne

15-16 June 2023 at the Peter Doherty Institute

About the workshop

The Wild Immunology group at the Menzies Institute for Medical Research, University of Tasmania is attempting to develop an oral bait vaccine to protect Tasmanian devils from the devil facial tumour disease (DFTD). Due to limited number of immunologists in Tasmania, the Menzies team is coming to Melbourne to engage with the rich immunology community in mainland Australia. Professor Katherine Kedzierska and Dr Louise Rowntree are helping us organise workshop at the Peter Doherty Institute (PDI) in Melbourne, Victoria on 15 June 2023.

Dr Andrew Flies will provide an overview of the two types of devil facial tumours (DFT1, DFT2), our current vaccine strategy, and constraints on the project at the PDI Department of Microbiology & Immunology seminar on 15 June. After the seminar there will be an afternoon tea, followed by two talks to prep workshop participants for breakout sessions to “Build a better DFT1/2 vaccine”. We hope to carry on discussions at Naughtons Hotel after the workshop. Members of the Wild Immunology group will be in Melbourne before and after the workshop, so we hope to setup other meetings with people interested in helping the Tasmanian devil. Contact andy.flies@utas.edu.au to register for the workshop or setup a meeting with one of our team members.

Thursday, 15 June 2023
0900 – 1200Wild immunology group arrives from Tasmania. Please arrange meetings if interested.
1200 – 1300PDI Department of Microbiology & Immunology seminar Andrew Flies – Menzies Institute for Medical Research, UTAS Developing a vaccine system for the Tasmanian devil facial tumour disease Room: PDI Auditorium; G004
1300 – 1345Discussion and afternoon tea Room: PDI Auditorium; G004
1400 – 1415Dr Ruth Pye – Menzies Institute for Medical Research, UTAS Previous DFT1 vaccine trials Room: Seminar Room GM002
1415 – 1430Dr Chrissie Ong – Menzies Institute for Medical Research, UTAS Analysing anti-DFT1 immunity
1430 – 1515Breakout groups: Build a better DFT1/2 vaccine Platform, antigens, delivery, immune correlates of protection
1530 – 1600Groups present their new and improved vaccine
1600 – 1645Synthesis, strategy, and funding
1700 – ?Continue discussion at Naughtons Hotel (https://naughtonshotel.com.au/) 43 Royal Parade, Parkville. Free nibbles provided by Menzies Institute
Friday, 16 June 2023
900 – 1030Individual meetings to continue conversations from workshop or pub
1030 – 1100Morning tea provided by Menzies Institute for Medical Research Room: GM002
1100 – 1200Vaccine design group discussions and funding plans. Room: GM002

Four new papers and grant for our Wild Immunology team!

Do we have a vaccine to stop devil facial tumour disease yet? No. Are we making progress? Yes. We published 4 papers in 3 months and won an Australian Research Council #LinkageProject grant. Read about here it here in The Conversation. Thank you to the Menzies Institute for Medical Research and the University of Tasmania for many years of support for our research!

https://theconversation.com/thousands-of-tasmanian-devils-are-dying-from-cancer-but-a-new-vaccine-approach-could-help-us-save-them-194536.

This Medical Life podcast features transmissible cancers in Tasmanian devils

The excellent hosts Dr Travis Brown and Steve Davis interview Ruth Pye and Andrew Flies from wild immunology group at the Menzies Institute for Medical Research.

https://omny.fm/shows/the-adelaide-show/transmissible-cancers

A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I

This is a small but critical first step towards developing an oral bait vaccine to protect Tasmanian devils from devil facial tumours! Congratulations to PhD student Ahab Kayigwe for leading this study. We hope to have this published in a peer-reviewed journal in the near future, but for now you can read the preprint here. https://doi.org/10.1101/2022.05.29.493930

Excited that an honours research project led to a manuscript and advances our Tasmanian devil oral bait vaccine research!

We are hoping to have this published in a peer-reviewed journal in the near future. More importantly we are already working to improved the baits for better delivery to devils.

Click here for the preprint article: Evaluation of oral baits and distribution methods for Tasmanian devils (Sarcophilus harrisii) https://doi.org/10.1101/2022.04.13.486902

Evaluation of oral baits and distribution methods for Tasmanian devils (Sarcophilus harrisii)

Really excited to see our low-budget honours project study turn into a manuscript. Note that this manuscript has not been peer reviewed yet, but we hope to see this published in 2022. This lays the foundation for the bait aspect of our oral bait vaccine to protect #Tasmanian #devils from the devil facial tumour disease #DFTD. We have a long way to go on the bait and vaccine but we are accelerating progress on both research streams and we have a great team in place to carry it forward. Congratulations to Sean Dempsey for taking on the challenge of getting this bait project started and climbing up several steep learning curves in 2021.

Read the pre-print paper here: https://www.biorxiv.org/content/10.1101/2022.04.13.486902v1

Here is a quick look at a dexterous devil grabbing a bait from the a bait dispenser.

Andrew Flies named the Australian Institute of Policy & Science Young Tall Poppy of the Year for 2020

Awards like these are only possible because of the incredible support from the my family, research team, and the Menzies Institute for Medical Research at the University of Tasmania.

Click to see Andy’s Tall Poppy page

Science in Pictures captures the essence of our Rewilding Immunology article!

Science in Pictures – Rewilding Immunology

https://www.scienceinpictures.com/comics/rewilding-immunology

Links to scientific publications and general information articles about COVID-19 vaccines in development

Folegatti, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (2020) doi:10.1016/s0140-6736(20)31604-4.

Zhu, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (2020) doi:10.1016/s0140-6736(20)31605-6.

Mercado, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature (2020) doi:10.1038/s41586-020-2607-z.

Wadman. Abortion opponents protest COVID-19 vaccines’ use of fetal cells. Science (2020). Not a peer-reviewed article.

What the HEK? A Beginner’s Guide to HEK293 Cells. BiteSizeBio. Not a peer-reviewed article.

The Immortal Life of Henrietta Lacks by Rebecca Skloot. A book that describes the first “immortal” human cells grown in culture, they are still alive today.

Tasmanian devil immunology research on WIN News Tasmania.